Wyeth Pharmaceuticals Development Pipeline (as of May 6, 2009)

Transcription

1 (as of May 6, 2009) Wyeth's R&D pipeline includes novel candidate medicines across our three platforms small molecules, vaccines, and biopharmaceuticals and we believe that many of these candidate medicines have the potential to be first-in-class, best-inclass, and/or first-in-therapy. Our development portfolio of new candidate medicines from Development Track to Registration, shown by therapeutic area and indication, is outlined below. We also have a discovery portfolio of 200 different projects and therapeutic targets. The information shown below is current as of May 6, Changes occur frequently and we undertake no obligation to update this information. Phase 0 PLA-950 (Inhaled) Asthma Musculoskeletal Disorders BMP-655 (Implantable) Surgical Repair of Tendons AAB-002 (IV) AAB-003 (IV) ACC-002 (IM) ILS-920 (IV) NRI-470 (oral) SAM-760 (oral) SBI-087 (SC)* VRA-175 (oral) Stroke Pain Multiple Sclerosis Pain inotuzumab ozogamicin (CMC-544)* CME-881 (IV) PKI-179 (Oral) PKI-587 (IV) Staphylococcus aureus* Indolent Non-Hodgkin s Lymphoma Solid Tumors Staphylococcus aureus May 6,

2 Phase 1 BLI-489 (IV)+ AGG-523 (Oral) ATN-103 (SC)+ ATN-103 (SC) ILV-094 (SC) ILV-095 (SC)+ SBI-087 (SC) SBI-087 (SC)+ Osteoarthritis Ankylosing Spondylitis, Crohn s Disease, Psoriatic Arthritis Rheumatoid Arthritis Psoriasis, Rheumatoid Arthritis Psoriasis Rheumatoid Arthritis Lupus/Systemic Lupus Erythematosus (SLE) Metabolic HSD-016 (Oral) OAP-189 (SC) Diabetes Obesity GSI-953 (Oral) HTC-867 (Oral) NSA-789 (Oral) NSA-789 (Oral) Cognitive Impairment Associated with Schizophrenia Cognitive Impairment Associated with Schizophrenia MnB rlp2086 (IM) Meningococcal Serogroup B (Infant) Women s Health PRA-027 (Oral) Uterine Fibroids May 6,

3 Phase 2 moxidectin (Oral Tablets) Tygacil (tigecycline) (IV) Tygacil (tigecycline)+ Onchocerciasis (River Blindness) Hospital-Acquired Pneumonia Pediatric Skin & Skin Structure IMA-026 (SC) TRU-015 (IV) Asthma Rheumatoid Arthritis Metabolic Relistor (methylnaltrexone bromide) (Oral) Opioid-Induced Constipation in Chronic Pain Musculoskeletal Disorders dibotermin alfa - CPM (BMP-2) (PC) dibotermin alfa - CPM (BMP-2) (Intraosseous)+ Fracture Repair Hip Osteoporosis ACC-001 (IM) bapineuzumab (AAB-001) (SC) Pristiq (desvenlafaxine succinate) (Oral Tablets) SAM-531 (Oral) vabicaserin HCI (SCA-136) (SR Capsules) Major Depressive Disorder (Pediatric) Bipolar Disorder bosutinib (SKI-606) (Oral) Breast Cancer inotuzumab ozogamicin (CMC-544) (IV)+ Diffuse Large B-cell Lymphoma / (Combination Therapy) neratinib (HKI-272) (Oral) Breast Cancer Combination Therapy MnB rlp2086 (IM) Meningococcal Serogroup B (Adolescent) May 6,

4 Phase 3 Tygacil (tigecycline) (IV) Diabetic Foot Infection bapineuzumab (AAB-001) (IV) bosutinib (SKI-606) (Oral) neratinib (HKI-272) (Oral)+ Torisel (temsirolimus) (IV) Chronic Myelogenous Leukemia Breast Cancer Monotherapy Renal Cell Carcinoma Combination Therapy 13vPnC (IM) Invasive Pneumococcal Disease (Adult) Women s Health bazedoxifene/conjugated estrogens (Oral Tablets) Menopausal Symptoms / Osteoporosis May 6,

5 Submitted for Registration Hemophilia BeneFIX Coagulation Factor IX (Recombinant) (IV) Hemophilia B (Japan) Enbrel (etanercept) (SC) Juvenile Rheumatoid Arthritis (Japan) Metabolic Protonix (pantoprazole sodium) (IV, granules)+ Gastrointestinal Reflux Disease (Pediatric) Torisel (temsirolimus) (IV) Torisel (temsirolimus) (IV) Mantle Cell Lymphoma (EU) Renal Cancer (Japan) Prevnar 13 Prevenar (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) (SC) Invasive Pneumococcal Disease (Infant) Invasive Pneumococcal Disease (Infant) (Japan) Women s Health Pristiq (desvenlafaxine succinate) (Oral Tablets) Viviant (bazedoxifene) (Oral Tablets) Menopausal Vasomotor Symptoms Osteoporosis May 6,

6 Removed from Active Status Since Last Report anrukinzumab (IMA-638) (SC) ATR-107 (SC) ATR-107 (SC) Asthma Crohn s Disease Lupus/Systemic Lupus Erythematosus (SLE) ERB-257 (IV) RAS-111 Sepsis Sepsis Pristiq (desvenlafaxine succinate) (Oral Tablets) GSI-136 (Oral) MMS-225 (Oral) PAZ-417 vabicaserin HCI (SCA-136) (SR Capsules) Fibromyalgia Multiple Sclerosis Schizophrenia inotuzumab ozogamicin (CMC-544) Follicular Non-Hodgkin s Lymphoma May 6,

7 The statements in this document that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, there can be no assurance that any of the candidate medicines identified above will be developed successfully into commercial products. Other risks and uncertainties that could cause actual results to differ materially from those expressed or implied by forward-looking statements include among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property, and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q, and annual report on Form 10-K, particularly the discussion under the caption Item 1A, Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, The forward-looking statements in this document are qualified by these risk factors. We assume no obligation to publicly update any forwardlooking statements, whether as a result of new information, future developments, or otherwise. Please note: Trademarks for products that have not received final regulatory approval are subject to change. May 6,